U.S. Stem Cell, Inc. (OTCMKTS: USRM) Shares Spike Higher By 38.89% On 3 Times Normal Trading Volume

(anyaivanova/Shutterstock.com) WETF01-pulse-040616-shutterstock Senior female tech in protective wear works in chemical lab

Shares of U.S. Stem Cell, Inc.  (OTCMKTS: USRM) shot up 38.89% on heavy trading volume on March 2, 2017. The stock price is has been extremely volatile over the last 4 trading sessions, trading in a range between $0.0141 and $0.0599.  According to OTC Markets, the stock over the last 30 days has traded around 22.45M shares per day, however; more than 65.1M shares traded yesterday. The stock price closed at $0.04, up $0.0112 on the session.

U.S. Stem Cell, Inc. (OTCMKTS: USRM) is ​a biotech company dedicated to expanding regenerative medicine.  The company caught our attention on February 27th, when first noticed the volume and volatility spike. Over the last five days the stock is up 138.63%. In addition, it’s up nearly 300% year-to date. Not only that, but historical volatility is relatively high as well. To put that into perspective, over the last ten days, the intraday volatility has been +/- 35.23%

With that said, we have not heard anything from U.S. Stem Cell, Inc. (OTCMKTS: USRM) that would explain the increase in the trading volume and stock price. Based on the close yesterday, the company had a market cap of $2.38M.


About U.S. Stem Cell, Inc.

Founded in 1999, U.S Stem Cell, Inc. has been committed to the development of effective cell technologies that treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function. U.S. Stem Cell’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.


Most Recent Headline:


CSO Kristin Comella Publishes Paper on the Implantation of Stromal Vascular Fraction in Patients with Degenerative Disc Disease

SUNRISE, FL / ACCESSWIRE / January 23, 2017 / US STEM CELL, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to announce our newest publication by our Chief Scientific Officer, Kristin Comella.

“Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease” was published in the January volume of the Journal of Translational Medicine. The study focused on the implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered directly into the damaged discs. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/28086781.

Ms. Comella’s previous paper, “Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy,” was released in the Journal of Translational Medicine‘s June 2016 edition. Using the same procedure, chronic ischemic cardiomyopathy patients were evaluated after SVF injection and able to walk more than 80 additional meters 3 to 6 months after treatment. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/27255774.

At U.S. Stem Cell, Inc., we are committed to new technological advancements and therapies that give a renewed sense of hope to patients with degenerative diseases. SVF is the latest therapy in a long line of successful treatments we have pioneered. Ms. Comella plans to continue her work with SVF, which has consistently repeated its strong safety profile and success in treating patients.

Don’t be surprised if the company comes out with a statement soon, updating us on this situation. Typically concerned companies will issue statements explaining if there is any new information to justify the increase in trading volume and stock price.If you’d like to keep up with biotech stocks like USRM, make sure to sign up to our newsletter below. It’s one of the best ways to stay in the loop with all that’s going on in the smallcap and OTC space.